. Author manuscript; available in PMC: 2018 Apr 1.

Published in final edited form as: Pediatr Infect Dis J. 2017 Apr;36(4):379–383. doi: 10.1097/INF.0000000000001450

Table 2.

Stool Inflammatory Markers and Immunosuppression

	Stool Calprotectin ug/g (median, IQR)		Stool Lactoferrin ng/mL (median, IQR)		Stool IL-8 pg/ml (median, IQR)
Malignancy Diagnosis
Yes (N=16)	8.6 (8.0–13.2)	P= 0.04	800 (0–5,800)	P< 0.01	0 (0–0)	P<0.01
No (N=12)	24.6 (8.4–265.2)		23,049 (5,814–62,457)		106.0 (0–428.8)

Immunosuppressant Use^*
Yes (N=22)	9.1 (8.2–18.1)	P=0.28	819 (414–18,330)	P=0.14	0 (0–0)	P=0.14
No (N=6)	37.0 (8.2–354.3)		20,691 (4,334–61,083)		62.0 (0–169.0)

30 days prior to symptom onset

Wilcoxon test